Resistance profile of entecavir in patients with chronic hepatitis B

Digestive and Liver Disease Supplements

Volumn 2, Issue 2, 2008, Pages 11-15

  Santantonio, T ^a   Fasano, M ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Antiviral drug resistance; Hepatitis B; Nucleos(t)ide analogues

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EXPOSURE; DRUG POTENCY; DRUG USE; GENE MUTATION; GENETIC RESISTANCE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; LONG TERM CARE; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 64349123352     PISSN: 15945804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1594-5804(09)60005-X     Document Type: Article

References (38)

1. Lok A., and McMahon B.J. AASLD Practice Guidelines. Chronic Hepatitis B. Hepatology 45 (2007) 507-539
2. Carosi G., and Rizzetto M. Treatment of chronic hepatitis B. Recommendations from an Italian workshop. Dig Liver Dis 40 (2008) 603-617
3. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol (2009) (in press).
4. Locarnini S., Hatzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 9 (2004) 679-693
5. Zoulim F., and Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 48 (2008) S2-19
6. Locarnini S., and Warner N. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antiviral Ther 12 Suppl.3 (2007) H15-H23
7. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64 (2004) 1-15
8. Locarnini S., and Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44 (2006) 422-431
9. Shaw T., Bartholomeusz A., and Locarnini S. HBV drug resistance: Mechanisms, detection and interpretation. J Hepatol 44 (2006) 593-606
10. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2 (2008) 147-151
11. Si Ahmed S.N., Tavan D., Pichoud C., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32 (2000) 1078-1088
12. Lok A.S., Zoulim F., Locarnini S., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46 (2007) 254-465
13. Pawlotsky J.-M., Dusheiko G., Hatzakis A., et al. Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a standardized approach. Gastroenterology 134 (2008) 405-415
14. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances e antigen serocon-version rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
15. Dienstag J., Goldin R., Heathcote E.J., et al. Histological outcome during long-term lamiviudine therapy. Gastroenterology 124 (2003) 105-117
16. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamuvidine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
17. Yuen M.F., Kato T., Mizokami M., et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 39 (2003) 850-855
18. Di Marco V., Marzano A., Lampertico P., et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40 (2004) 883-891
19. Mutimer D., Pillay D., Schields P., Cane P., Ratcliffe D., Martin B., et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2 46 (2000) 107-113
20. Thibault V., Aubron-Olivier C., Agut H., and Katlama C. Primary infection with lamivudine-resistant hepatitis B virus. AIDS 16 (2002) 131-133
21. Torresi J., Earnest-Silveira L., Deliyannis G., et al. Vaccine-induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 (2002) 305-313
22. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 39 (2003) S124-S132
23. Fung S.K., and Lok A. Management of hepatitis B patients with antiviral resistance. Antiviral Ther 9 (2004) 1013-1026
24. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimcrob Agents Chemother 48 (2004) 3498-3507
25. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
26. Lok A., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
27. Marcellin P., Chang T.-T., Lim S.L., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Hepatology 48 (2008) 750-758
28. Hepsera (adefovir dipivoxil) prescribing information (2006), Gilead Sciences, Foster City CA. http://www.gilead.com/pdf/hepserapi.pdf (http://www.gilead.com/pdf/hepsera_pi.pdf)
29. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
30. Lai C.-L., Gane E., Liaw Y.-F., et al. Telbivudine versus Lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
31. Lai C.-L., Gane E., Hsu C.-W., et al. Two-year results from the GLOBE trial in patients with epatiti B: greater clinical and antiviral efficacy for Telbivudine (LDT) vs Lamivudine. Hepatology 44 Suppl 1 (2006) 222A Abstract 91
32. Marcellin P., Jacobson I., Habersetzer, et al. Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: week 72 TDF data and week 24 Adefovir Dipivoxil switch data (Study 102). EASL (2008) Abstract 57
33. Heathcote J., George J., Gordon S., et al. Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: week 72 TDF data and week 24 Adefovir Dipivoxil switch data (Study 103). EASL (2008) Abstract 72
34. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
35. Tenney DJ, Pokornowski KA, Rose RE, et al., Long-term resistance profile of entecavir in nucleoside-naive patients with chronic hepatitis B from worldwide and Japanese development programs. EASL, AASLD, APASL, ALEH, IASL Conference: Hepatitis B and C virus resistance to antiviral therapies. Paris, France, February 14-16, 2008. Abstract 55, p. 77.
36. Tenney D.J., Pokornowski K.A., Rose R.E., et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance (2008), Hepatology International A88 Abstract PL02.
37. Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
38. Tenney DJ, Pokornowski KA, Rose RE, et al., Long-term resistance profile of entecavir in lamivudine-refractory patients with chronic hepatitis B from worldwide and Japanese development programs. EASL, AASLD, APASL, ALEH, IASL Conference: Hepatitis B and C virus resistance to antiviral therapies. Paris, France, February 14-16, 2008. Abstract 56, p. 78.